These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22749329)

  • 21. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
    Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
    Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Periprocedural anticoagulation management of patients with venous thromboembolism.
    McBane RD; Wysokinski WE; Daniels PR; Litin SC; Slusser J; Hodge DO; Dowling NF; Heit JA
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):442-8. PubMed ID: 20139361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    Andras A; Sala Tenna A; Stewart M
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.
    van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
    J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
    Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
    Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?
    Khorana AA; Yannicelli D; McCrae KR; Milentijevic D; Crivera C; Nelson WW; Schein JR
    Thromb Res; 2016 Sep; 145():51-3. PubMed ID: 27485998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy.
    Spyropoulos AC; Frost FJ; Hurley JS; Roberts M
    Chest; 2004 May; 125(5):1642-50. PubMed ID: 15136371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials.
    Deerhake JP; Merz JC; Cooper JV; Eagle KA; Fay WP
    J Thromb Thrombolysis; 2007 Apr; 23(2):107-13. PubMed ID: 17221327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
    Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study.
    Skeith L; Taylor J; Lazo-Langner A; Kovacs MJ
    J Thromb Haemost; 2012 Nov; 10(11):2298-304. PubMed ID: 22925003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation.
    Wysokinski WE; McBane RD; Daniels PR; Litin SC; Hodge DO; Dowling NF; Heit JA
    Mayo Clin Proc; 2008 Jun; 83(6):639-45. PubMed ID: 18533080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
    Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
    Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.
    Ihaddadene R; Le Gal G; Delluc A; Carrier M
    Thromb Res; 2014 Jul; 134(1):93-5. PubMed ID: 24835673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.
    Carrier M; Le Gal G; Cho R; Tierney S; Rodger M; Lee AY
    J Thromb Haemost; 2009 May; 7(5):760-5. PubMed ID: 19245418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
    Fuentes HE; Oramas DM; Paz LH; Casanegra AI; Mansfield AS; Tafur AJ
    Thromb Res; 2017 Jun; 154():28-34. PubMed ID: 28402864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.
    Labrador J; González-Rivero J; Monroy R; Lozano FS; López-Corral L; Caballero MD; Bastida JM; González-Porras JR
    Thromb Res; 2016 Jun; 142():52-6. PubMed ID: 26922092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.